A Case of Anaplastic Large Cell Lymphoma with DUSP22 Rearrangement

EHA-TSH Hematology Tutorial 2024 June 29-30, 2024 Ankara

Umut Yılmaz, MD Istanbul/Turkey







ALCL Case Presentation- Disclosures

Umut Yılmaz

Janssen Pharmaceuticals - Speaker



Initial presentation and history (December 2020)


39 year-old male

Annual follow-up (asymptomatic)

Papillary thyroid carcinoma (2016)

20 x 15mm cervical lymph node detected in neck US

Initial PET/CT (December 2020) and excisional biopsy



Pathology Report

- Anaplastic Large T Cell Lymphoma (ALCL), ALK negative
- Ki-67= 80-90%
- 6p25.3 rearrangement in 48% of the cells on FISH (DUSP22)

Pre-treatment evaluation

Bone marrow aspiration and biopsy: No lymphoma involvement

Thyroid cancer in long-term remission after thyroidectomy

Normal cardiac, renal, hepatic function, and normal LDH level

ECOG = 0

No tumor burden after diagnostic excision




Pre-treatment evaluation (summary)

Stage 1, ECOG = 0 IPI= 0 / IPTCLP= 0 PIT= 0 /mPIT= 1 TMTV = low (none), DUSP22 mutated Age 39, Excellent organ function

> IPI= international prognostic index IPTCLP=international peripheral T cell lymphoma project score PIT= prognostic index T cell lymphoma


TMTV= total metabolic tumor volume

Prognostic data to take into account



ANC ≤ 6.5 x10⁹/L

Prognostic data to take into account (TMTV and early response)




Cottereau AS, et al. PJ Nucl Med. 2018;59(4):589-595.




Prognostic data to take into account (TLG)

Total Lesion Glycolysis (MTV x SUVmean)




Kitadate A, et al.. Cancer Med. 2020;9(15):5509-5518

Prognostic data to take into account (DUSP-22 rearrangement)



Parrilla Castellar, et al. Blood. 2014;124(9):1473-1480

Prognostic data to take into account (DUSP-22 and PS)



Sibon D, et al. Haematologica. 2023;108(6):1590-1603.



Treatment

- First step: Detailed discussion with the patient regarding treatment options:
 - ✓ The patient prioritizes cure at the cost of over-treatment
- Plan: 6 cycles of CHOEP followed by ASCT
 - ✓ No significant complication during CHOEP
 - ✓ Uneventful ASCT
 - ✓ Remains in remission as of May, 2024 (3.5 years)
 - ✓ No long-term complications of treatment at this point



Thank You For Your Attention